Since its earliest days, Fred Hutch Cancer Center’s story has been closely tied to bone marrow transplantation. E. Donnall Thomas, MD, Fred Hutch’s first director of medical oncology, pioneered this approach, harnessing the power of the immune system to treat leukemia and other blood diseases.
On this episode of the Oncology Insights Podcast, host Petros Grivas, MD, PhD, FASCO, sits down with Marco Mielcarek, MD, PhD, director of the Blood and Marrow Transplant Program at Fred Hutch. Together, they discuss the changes Mielcarek has seen over a career spanning more than three decades, as well as the latest advancements that are making transplantation safer and more accessible for patients.
Mielcarek’s research focuses on graft-vs.-host disease, or GVHD, a potentially life-threatening complication in which newly transplanted cells attack the patient’s body. Mielcarek and his research colleagues are testing in clinical trials how to better prevent GVHD and how to effectively treat it without causing unwanted toxicity. They have shown that carefully timed infusions of high doses of cyclophosphamide, a common chemotherapy drug, can safely and effectively prevent GVHD after growth factor-mobilized blood stem transplantation.
Key Takeaways:
Mielcarek’s personal journey from Berlin to Seattle and his long-standing contributions since 1994
Key progress in stem cell transplantation, including the role of Nobel laureate E. Donnall Thomas, MD
Strategies to manage and reduce graft-vs.-host disease (GVHD) over the decades
The impact of post-transplant cyclophosphamide technology in expanding donor pools and reducing complications
How outpatient care models are revolutionizing patient recovery and follow-up after transplantation
The future of transplantation: safer, less toxic regimens and targeted therapies like CAR T cells
The importance of becoming a donor through the National Marrow Donor Program and how donors help save lives
YouTube | Spotify | Apple Podcasts | Libsyn | Amazon Music